Evaluation of the novel culture-based AtbFinder test-system for the selection of optimal antibiotics for critically ill patients with polymicrobial infections within 4 h

George Tetz¹, Victor Tetz¹*

¹ Human Microbiology Institute, New York, NY, USA;  g.tetz@hmi-us.com

* Correspondence: g.tetz@hmi-us.com

**Abstract:** Here we describe the validation of a new phenotypic culture-based AtbFinder method for rapid selection of antibiotics in vitro using specimens with mono- and polybacterial infections. AtbFinder, which can be applied to any type of non-blood tissue, does not require isolation of pure bacterial cultures. The method uses a novel TGV medium that allows more rapid bacterial growth of Gram-positive and Gram-negative monoisolates compared with that achieved with conventional laboratory media and demonstrated overall sensitivity, specificity, PPV, NPV values of 99.6%, 98.1%, 98.5%, and 99.4%, respectively, already after 4h.

For polymicrobial infections, AtbFinder utilizes a novel paradigm of the population response to antibiotics, enabling bacterial growth in the form of a mixed microbial community and selecting the antibiotics targeting not only the principal pathogen, but also those bacteria that support their growth. TGV medium allowed culturing a more diverse set of bacteria from polymicrobial biospecimens, compared with that achieved with the standard media and enabled, already within 4h, accurate selection of the antibiotics that completely eliminated all cultivatable bacteria from clinical samples. In conclusion, AtbFinder system may be a valuable tool in improving antibiotic selection, enabling targeted empirical therapy and accurate antibiotic replacement, which is especially important in high-risk patients.

**Keywords:** antibiotic resistance, antimicrobial susceptibility testing, novel diagnostics, polymicrobial, sputum, drug resistant

1. Introduction

Antibiotic therapy is typically started on an empirical basis, because the causative organism is not identified in an appreciable proportion of patients (1-3). However, empirical antibiotic therapy is inadequate in over 25% of cases, with 8–12% of patients receiving antibiotics that are ineffective (4). For these patients, antibiotic therapy must be adjusted following antimicrobial susceptibility testing (AST) by culture-based and/or molecular biology methods. However, even following the switch of the empirically chosen antimicrobial, in over 10% of cases, the newly selected antimicrobial remains...
ineffective (3). The resulting clinical failure is particularly dangerous for immunocompromised patients.

There are several types of diagnostic tests used currently for the selection of appropriate antibiotics, but neither of them is ideal with regard to its expedience and accuracy (5). Currently, traditional methods based on the isolation of bacterial culture, require at least 24 h to detect the growth of bacteria isolated from clinical specimens after sampling and another 6 to 24 h for detailed isolate characterization (i.e., biochemical identification) or susceptibility testing, during which time the treatment can only be empirical (6, 7). Therefore culture-based methods, owing to the slow turnaround time of results, are not suitable for tailored empirical therapy and are suboptimal in acute infection cases.

Another concern with culture-based tests is that media used in classical AST techniques, such as LB, Columbia and others, do not allow the growth of complex polymicrobial communities (8, 9). As a result, some clinically relevant organisms that are more difficult to culture do not get detected by standard AST of biological samples, leading to therapy failure (9). Many contemporary methods allow isolation of only the predominant species, whereas bacteria at the site of infection are rarely represented by a single species (10). The vast majority of the infections of the respiratory tract, urinary tract, skin, and soft-tissues had been previously characterized as being monomicrobial due to inaccurate results from culture-dependent isolation techniques. In contrast, the use of more advanced methods today indicates their polymicrobial nature (8, 11-14). Bacteria within polymicrobial communities are significantly more resistant to antimicrobials as they share collective antibiotic resistance (15). Furthermore, they are characterized by combined virulence contributing to the increased mortality rate among critically ill and compromised patients, such as patients with HIV or those that underwent solid organ or marrow transplantation (10, 16-18).

Another reason for the inappropriate selection of antibiotics by the standard AST methods is that they focus only on well-known pathogenic bacteria (8, 19). However, many bacteria that are considered nonpathogenic in non-immunocompromised patients may be pathogenic in people with suppressed immune response (20). This may happen because even in the case of successful elimination of one specific pathogen with a selected antibiotic, other bacteria that remain at the site of infection continue to grow and result in disease progression. Moreover, there is no benchmark accurate enough to indicate with certainty that bacteria are definitely pathogenic (21). For example, Pandoraea apista, Aeromonas spp., and Kluyvera spp. are now classified as pathogenic, although several decades ago, they were believed to be opportunistic and safe microorganisms (21-24). The media used in standard AST mostly promote the growth of the predominant bacteria and do not necessarily support proliferation of minor bacterial species from biological samples that may depend on each other for growth (25). That is why, it has been estimated that less than 10% of bacteria can be cultured in laboratory conditions and assayed by conventional AST (26-28).

In order to overcome these obstacles, in the last few decades, several types of novel diagnostic tests for rapid identification of bacteria and AST have been developed (29, 30). Such tests are based on direct pathogen identification using nucleic acid amplification techniques (5, 31). Although these methods are frequently utilized to determine the causative agents of bloodstream infections, some of them are used for the infections of other parts of the body (32-34). These methods do not depend on in vitro growth for bacterial detection and have become routine in many clinical microbiology laboratories. The introduction of PCR assays and sequencing technologies shortened the
turnaround time to obtain the results and enabled characterization of polymicrobial infections (35, 36). However, these assays also have a number of limitations. In particular, although the identification of bacteria helps to determine the therapeutic strategy, it does not really inform on the extent of resistance to antibiotics (6). Moreover, the methods based on 16S RNA sequencing are not very accurate as many bacterial species share similar or identical 16S rRNA sequences (37, 38). Some molecular biology methods are based on the detection of antimicrobial resistance genes (39, 40). However, the reliance on the presence of resistance genes may be misleading with regard to accurate antibiotic selection as not all resistant genotypes result in resistant phenotypes (6). Furthermore, these methods can only detect known antibiotic resistance genes but may omit those, which have not yet been discovered (39, 41). The available resistance markers are not sufficiently comprehensive to provide clinically actionable results and may lead to the usage of either unnecessarily broad spectrum antibiotics or those without the sufficiently strong therapeutic effect.

Consequently, culture-based AST that predicts not only the resistance but also susceptibility to different drugs is still considered the gold standard for the identification of the most appropriate antibiotic for various infections (42).

Here, we evaluated a novel culture-based AtbFinder system that utilizes the recently developed TGV medium that supports simultaneous growth of a significantly more diverse set of bacteria from biological samples compared with that achieved with conventional laboratory media and uses a novel paradigm for rapid phenotypic-based antibiotic selection for monobacterial and polybacterial clinical isolates.

The AtbFinder approach is based on a novel paradigm for the selection of effective antibiotics that considers not only monobacterial infection but also polybacterial cooperative interactions at the infection site.

2. Materials and Methods

Study samples and laboratory settings

Study specimens were obtained from the Human Microbiology Institute (New York, NY, USA), maintained at about 4 °C (wet ice), but not frozen, and sent to TGV-Biomed within 8 h after sampling.

Bronchoalveolar lavage (BAL) or sputum samples obtained from patients with chronic obstructive pulmonary disease (COPD), community-acquired pneumonia (CAP), ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), cystic fibrosis (CF) were tested by using both state-of-the-art methods and AtbFinder system.

Antibiotics

AST was limited to antibiotics used for the treatment of respiratory infections, which were selected according to the American Thoracic Society/Infectious Disease Society of America guidelines (43–45). Antibiotics were added to TGV medium at respective maximal concentrations that could be achieved at the site of infection according to literature data: amikacin, 9 µg/mL (46); azithromycin 8 µg/mL (46, 47); aztreonam 22 µg/mL (48, 50); cefepime 24 µg/mL (46, 49, 50); gentamicin 5 µg/mL (46, 51); levofloxacin 12 µg/mL (46, 52); linezolid 25 µg/mL (53, 54); meropenem 10 µg/mL (55); piperacillin-
tazobactam (25 for piperacillin and 3.5 for tazobactam) µg/mL (56); vancomycin 12 µg/mL (46, 57) (all from Sigma-Aldrich, St. Louis, MO). Probes were incubated at 37 °C, for 4, 8, and 24 h.

Bacterial strains and growth conditions

Bacterial clinical isolates used as monobacterial cultures for the validation of bacterial population diversity and growth speed the TGV agar included the following Gram-positive and Gram-negative bacteria: S. aureus (n = 22), Streptococcus pneumoniae (n = 4), Streptococcus epidermidis (n = 4), Streptococcus pyogenes (n = 2), Enterococcus faecalis (n = 5), Bacillus cereus (n = 4), Paenibacillus VT400 (n = 1), Bacillus respiratorii VT-16-64 (n = 1) Escherichia coli (n = 15), Acinetobacter baumannii (n = 2), Stenotropomonas maltophilia (n = 4), Klebsiella pneumoniae (n = 10), Proteus vulgaris (n = 4), Proteus mirabilis (n = 5), Haemophilus influenzae (n = 1), Klebsiella oxytoca (n = 1), Rothia mucilaginosa (n = 1), Moraxella catharrhalis (n = 1) Pseudomonas aeruginosa (n = 16), Burkholderia cenocepacia (n = 6), Enterobacter cloacae complex (n = 6), Achromobacter xylosoxidans (n = 2), Serratia marcescens (n = 3).

Bacteria were obtained from the Cystic Fibrosis Foundation Therapeutics Development Network Resource Center for Microbiology at the Seattle Children’s Hospital (Seattle, WA, USA) and from the Human Microbiology Institute (New York, NY, USA). Individual patterns of resistance to antibiotics are summarized in Supplementary Table 1.

All bacterial strains were subcultured from frozen stocks onto Columbia broth (Oxoid Ltd., London, England) and incubated at 37 °C overnight. A standard bacterial inoculum of 5 × 10⁴ CFU/mL was used. All subsequent liquid subcultures were derived from colonies isolated from these plates and were further grown at different solid media: LB agar (Oxoid Ltd., London, England), Columbia agar (Oxoid Ltd., London, England), Brain heart infusion agar (Oxoid Ltd., London, England), Burkholderia cepacia-selective agar (Hardy Diagnostics, Santa Maria, CA), chocolate agar (Oxoid Ltd., London, England), Mueller-Hinton broth (Oxoid Ltd., London, England), CHROMagar Staph aureus Medium (Becton, Dickinson and Company, Franklin Lakes, NJ), TGV medium (Human Microbiology Institute, New York, NY, USA). All media were supplemented with 5% lysed sheep erythrocytes (Becton Dickinson, Heidelberg, Germany).

Biological specimen processing and bacterial isolation from them

This study was approved by the Institutional Review Board and Ethics Committee of Human Microbiology Institute (Number: 018-4-AF). BAL or sputum biospecimens (1 mL) from the patients with ventilator-associated, community-acquired pneumonia, cystic fibrosis, or chronic obstructive pulmonary disease were mixed with 1 mL of sterile H2O until homogeneity with a plastic swab. After homogenization, 25 µL of the suspension was directly plated onto TGV agar in each well of 12-well plate and incubated at 37 °C, for 4, 18, and 24 h. For control arm, 100 µL suspension were plated on 90 mm Petri dish with LB agar, Burkholderia cepacia-selective agar (Hardy Diagnostics), chocolate agar (Oxoid) or CHROMagar Staph aureus Medium (Becton, Dickinson and Company) and cultured according to laboratory recommendations at 37°C for 24 – 72 h (8). The results of the study were not reported to the physician, and no medical decisions were made on the basis of these data.

Identification of bacteria in biological specimens
Bacterial identification to the species level from biological specimens was done by using subcultures on AtbFinder or LB medium (Oxoid, UK). Isolates were examined for purity by light microscopy (Leica 2500DM, Leica Microsystems, Germany). To exclude the presence of mixed bacterial cultures, the isolates were assessed from at least 10 fields of view (58). After the subcultivation of every mixed bacterial culture up to monocultures, subsequent biochemical identification and matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (Microflex LT, Bruker Daltonics, Germany) analysis were performed according to the manufacturer’s instructions after 24 h of growth.

The complete 16S rRNA gene sequencing of bacterial colonies was also used to identify the isolates. A PCR was performed with the general bacterial primers 27f (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492r (5′-GGTTACCTTGTTACGACTT-3′). The PCR mixture contained 0.2 μM of each primer and 40 ng of bacterial DNA in a total volume of 100 μL (HotStar Taq Master Mix Kit, Qiagen, Valencia, CA, USA) [59].

PCR was performed with a Mastercycler EP S gradient thermocycler (Eppendorf, Germany) using the following protocol: one cycle of 15 min at 95 °C, followed by 30 cycles, of (60 s at 95 °C, 45 s at 50 °C, and 90 s at 72 °C), and the final extension cycle of 10 min at 72 °C. The PCR products were verified by electrophoresis in 0.8% agarose gel, and the rest of the sample was purified and concentrated in 30 μL of demineralized water using a Qiaquick PCR purification kit (Qiagen) (60).

PCR amplicons were sequenced with a BigDye Terminator v1.1 cycle sequencing kit (Life Technology, Foster City, CA, USA). Identification to the species level was conducted by comparing the obtained sequences with those in BLAST database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Identifications to the genus and species-level were done on the basis of ≥97% and 99% identity of the 16S rRNA gene sequence to the reference, respectively (61).

AtbFinder system and interpretation of results
AtbFinder system is a multi-well (12, 24 or 96) (Sarstedt, Newton, NC, USA, TGV-Dx, USA) filled with TGV-T medium that comprises pancreatic digests of casein, peptic digest of meat, heart pancreatic digest, yeast extract, starch, and water (Human Microbiology Institute, New York, NY, USA).

Clinical specimens were directly plated onto TGV agar in each well with a sterile swab, avoiding scratching or damaging the agar. Ten of the twelve wells contained TGV agar with antibiotics (one antibiotic per well) at concentrations that can be practically achieved at the site of infection. Two control wells contained antibiotic-free TGV agar. Plate reading was performed following sampling and incubation at 37 °C, for 4, 8, and 24 h.

The presence of microbial growth was identified with the naked eye and confirmed with a stereoscopic microscope (Leica S6, Leica Microsystems, Germany). The signs of early bacterial growth, namely hemolysis, appearance of film, and microcolonies, in the wells with antibiotics were compared with signs of bacterial growth in control wells.
Microbial growth in any well meant that in the biospecimens, there were microorganisms resistant to the particular antibiotic in the nutrient medium in the well; therefore, the antibiotic was categorized as “ineffective”. An absence of bacterial growth in the well meant that the antibiotic present in the well had killed or inhibited the growth of all bacteria in the biospecimens and was thus categorized as “effective”. In rare cases, there was no growth in control wells after 4 h, so those cultures were not analyzed further as is separately described in the Results below.

**Gold standard definition**

Culture-based *in vitro* AST was selected as the standard of care method. The minimal inhibitory concentrations (MICs) for antimicrobials were determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (62, 63). The isolates were categorized as susceptible or resistant according to CLSI breakpoint guidelines with the only modification that “intermediate” isolates were treated as “resistant” (64). A standard bacterial inoculum of 5 \times 10^5 CFU/mL was used. Serial twofold dilutions of the antimicrobials were prepared in cation-adjusted Mueller-Hinton broth. MIC was defined as the lowest concentration of antibiotic that completely inhibited visible growth. Experiments were conducted in triplicate.

**Data analysis**

The results of antibiotic selection from the AtbFinder system were compared to those obtained with the culture-based gold standard microdilution method. For the purpose of data analysis, the following definitions were used. A true-positive result occurred when both the AtbFinder and standard-of-care methods indicated that the microorganism was resistant to the antibiotic. A true-negative result occurred when both AtbFinder and standard-of-care methods demonstrated sensitivity of the microorganism to the antibiotic. A false-positive result occurred when the AtbFinder system identified a strain as being sensitive to a certain antibiotic, but according to the standard-of-care method, the organism was resistant to that antibiotic. A false-negative result was recorded when the AtbFinder system suggested that the microorganism was resistant to the antibiotic, whereas the standard-of-care method indicated that it was sensitive. We calculated the values of accuracy, sensitivity, specificity, as well as positive predictive value (PPV) and negative predictive value (NPV) as previously described (65).

The total category agreement (CA) was determined and the results which differed from those obtained by the state of care microdilution method were categorized as described previously (66). Thus, the very major errors were recorded in the cases when the AtbFinder system indicated that an isolate was susceptible to the antibiotic, whereas according to the standard of care method, the isolate was resistant. The major errors were recorded in the cases when the AtbFinder system suggested that an isolate was resistant to the antibiotic, whereas the standard of care method indicated that the isolate was susceptible. The rate of very major errors was calculated by dividing the total number of very major errors by the total number of strains determined as being resistant and multiplied by 100%. The rate of major errors was determined by dividing the total number of major errors by the number of strains determined as being susceptible and multiplied by 100%.
Bacterial diversity analysis

The variety of bacteria that grew on the media used was characterized by the α-diversity indices such as non-parametric abundance-based coverage estimator (ACE) and Chao 1, indices which were managed and analyzed using R version 3.4.1 software (67). Species richness (a count of different species), that gave growth on different media were represented on a dot plot, generated by package ‘ggplot2’ within R version 3.4.1 (67). All statistical analyses were conducted with a significance level of α = 0.05 (P < 0.05).

Statistics

Two-way ANOVA comparisons test was applied within the same data sets to test difference between microbial growth on different media at each time point. GraphPad Prism version 9 (GraphPad Software, CA, USA) or Excel 10 were applied for statistical analysis and illustration was used if not stated differently. P values < 0.05 were significant.

3. Results

3.1 Comparison of bacterial growth rate on TGV medium to that on other media

We first performed a validation of TGV agar by using monomicrobial cultures to confirm that it enables faster bacterial growth compared with that afforded by the conventional LB agar, Columbia agar or brain heart infusion (BHI) agar. After 4 h of cultivation, visible growth was detected in 119 of 122 monomicrobial cultures (97.5%) in plates with TGV medium. Visible growth was not detected after 4 h only for Stenotrophomonas maltophilia (n = 1), Streptococcus pneumoniae (n = 1), and Acinetobacter baumannii (n = 1). However, these three strains became visible already after 8 h in culture (122/122; 100%) (Fig. 1A).

Under the same conditions, visible growth on other agar media after 4 h of culturing was detected for fewer microorganisms. In particular, culturing on LB agar revealed growth of only 69 out of 122 strains (56.5%), whereas 89 out of 122 strains (72.9%) grew on Columbia agar and 87 out of 122 strains (71.3%) grew on BHI agar. Moreover, some Streptococcus spp. did not reveal clear growth even after 8 h on these media and became visible only by 24 h (Fig. 1A). We also analyzed the effect of different media on the speed of growth of the key respiratory pathogens Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae (Fig. 1B–D). We found that TGV media enabled the fastest growth with 100% strains being visible within the first 4 hours post plating, compared with lower numbers of positive bacterial growth detected in the plates filled with LB agar, Columbia agar, or BHI agar (p<0.05).
Figure 1. Comparative analysis of bacterial growth rate in different media (A) Growth rate is represented by a heat map with each cell indicating the percentage of bacterial strains that gave growth at 4, 8, or 24 h. Red color intensity represents the highest rate of growth, whereas white color indicates no growth for a particular time period. (B) Number of S. aureus strains out of 22 tested that gave visible growth at different time periods on different media: TGV agar (TGV), LB agar (LB), Columbia agar (COL), or brain heart infusion agar (BHI). (C) Number of P. aeruginosa strains out of 16 tested that gave visible growth at different time periods on TGV, LB, COL, or BHI. (D) Number of K.
pneumoniae strains out of 10 tested that gave visible growth at different time periods on TGV, LB, COL, or BHI.

We observed higher species richness after growth for 4 h on TGV medium as revealed by ACE and Chao 1 indices (28.07 and 33.5, respectively), compared with the values of these parameters after growth on LB agar (ACE = 25.6 and Chao 1 = 21.5) or Columbia agar (ACE = 25.5 and Chao 1 = 24; Fig. 2A, B). Therefore, TGV was the only medium that allowed to detect visible growth of monomicrobial cultures already after 4 h with high accuracy.

**Figure 2.** Increased diversity of bacterial species that gave growth on TGV medium, compared to that of species that grew on LB and Columbia agar, as revealed by the values of abundance-based coverage estimator (ACE), A) and Chao1 (B) indices.
3.2 Estimation of the diversity of bacteria grown on TGV medium

Next, we applied TGV medium for the studies of polymicrobial infections. We used samples from patients with respiratory infections, which are usually associated with polymicrobial growth. Bacterial growth on TGV medium was seen within 4 h in 20 out of 20 clinical specimens (100%), whereas microbial growth was detected only in 8 out of 20 samples (40%) grown on LB agar that was used as standard medium. Only subsequent growth for 24 h revealed clear bacterial growth in all samples cultured in LB media.

Next, we analyzed polymicrobial growth in each sample by using TGV and LB media at 4 h and 24 h of culturing. A detailed description of bacteria that gave growth on different media is provided in Table 1.

Table 1. Comparison of diversity values of bacteria grown on AtbFinder and standard media for 4 and 24 h.

| # | Clinical specimen | Diagnosis | Bacteria that gave growth on TGV medium | Bacteria identified with standard media* |
|---|-------------------|-----------|----------------------------------------|-----------------------------------------|
|   |                   |           | 4 h                                    | 24 h                                    | 4 h                                    | 24 h                                    |
| 1 | BAL               | COPD      | Burkholderia gladioli                  | B. gladioli                            | Neisseria spp.                         | Neisseria spp.                         | H. parainfluenzae                      | S. mitis                               | R. mucilaginosa                        |
|   |                   |           | Haemophilus parainfluenzae             |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | S. mitis                               |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | R. mucilaginosa                         |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | Streptomyces violacerubrum             |                                        |                                        |                                        |                                        |                                        |                                        |
| 2 | BAL               | COPD      | S. aureus                              | S. aureus                              | K. pneumoniae                          | K. pneumoniae                          |                                        |                                        |                                        |
|   |                   |           | K. pneumoniae                          |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | E. coli                                |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | E. faecalis                            |                                        |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | Proteus spp.                           |                                        |                                        |                                        |                                        |                                        |                                        |
| 3 | BAL               | CAP       | S. aureus                              | S. aureus                              |                                        |                                        | S. aureus                              |                                        |                                        |
|   |                   |           | S. pneumoniae                          | S. pneumoniae                          |                                        |                                        |                                        |                                        |                                        |
| 4 | BAL               | CAP       | S. aureus                              | S. aureus                              |                                        |                                        | S. aureus                              |                                        |                                        |
| 5 | BAL               | CAP       | P. aeruginosa                          | P. aeruginosa                          |                                        |                                        | P. aeruginosa                          |                                        |                                        |
|   |                   |           | H. influenza                           | H. influenza                           |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | M. catarrhalis                         | M. catarrhalis                         |                                        |                                        |                                        |                                        |                                        |
| 6 | BAL               | VAP       | S. aureus                              | S. aureus                              |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | E. cloacae                             | E. cloacae                             |                                        |                                        |                                        |                                        |                                        |
|   |                   |           | P. aeruginosa                          | P. aeruginosa                          |                                        |                                        |                                        |                                        |                                        |
| No. | Sample Type | Condition | Bacteria 1 | Bacteria 2 | Bacteria 3 | Bacteria 4 |
|-----|-------------|-----------|------------|------------|------------|------------|
| 7   | BAL VAP     | S. aureus | S. aureus  | -          | S. aureus  |
|     |             | K. pneumoniae | K. pneumoniae |           | E. coli    |
|     |             | E. coli   | E. coli    |            |            |
|     |             | C. mucoviscidosis | C. mucoviscidosis |        |            |
|     |             | S. aureus | S. aureus  |            |            |
| 8   | Sputum CF   | P. aeruginosa | P. aeruginosa | P. aeruginosa | P. aeruginosa |
|     |             | S. aureus | S. aureus  |            |            |
|     |             | R. mucilaginosa | R. mucilaginosa |        |            |
| 9   | Sputum CF   | P. aeruginosa | P. aeruginosa | -          | P. aeruginosa |
|     |             | S. aureus | S. aureus  |            |            |
|     |             | S. maltophilia | S. maltophilia |        | B. cepacia |
|     |             | B. cepacia | B. cepacia |            |            |
| 10  | Sputum CF   | P. aeruginosa | P. aeruginosa | -          | P. aeruginosa |
|     |             | Micrococcus luteus | M. luteus |        |            |
|     |             | S. aureus | S. aureus  |            |            |
|     |             | S. oralis | S. oralis  |            |            |
|     |             | S. milleri | S. milleri |            |            |
| 11  | Sputum CF   | P. aeruginosa | P. aeruginosa | P. aeruginosa | P. aeruginosa |
|     |             | A. xylosoxidans | A. xylosoxidans |        |            |
|     |             | E. coli   | E. coli    |            |            |
| 12  | Sputum CF   | S. maltophilia | S. maltophilia | P. aeruginosa | P. aeruginosa |
|     |             | E. coli   | E. coli    |            |            |
|     |             | Bacillaceae spp | Bacillaceae spp |        |            |
|     |             | P. aeruginosa | P. aeruginosa |            |            |
| 13  | Sputum CF   | P. aeruginosa | P. aeruginosa | -          | P. aeruginosa |
|     |             | S. haemoliticus | S. haemoliticus |        |            |
|     |             | A. baumannii | A. baumannii |        |            |
|     |             | A. xylosoxidans | A. xylosoxidans |        |            |
|     |             | B. thailandensis | B. thailandensis |        |            |
| 14  | Sputum CF   | B. multivorans | B. multivorans | -          | C. pseudodiphtheriticum |
|     |             | Corynebacterium pseudodiphtheriticum | C. pseudodiphtheriticum |        |            |
|     |             | Moraxella catharrhalis | Moraxella catharrhalis |        |            |
|     |             | Paenibacillus pabuli | Paenibacillus pabuli |        |            |
|     |             | M. catharrhalis | M. catharrhalis |        |            |
| Sample  | Media  | Bacterial Species |
|---------|--------|-------------------|
| 15 Sputum CF | A. xylosoxidans, R. mucilaginos, E. miricola, M. paraoxydans | A. xylosoxidans, R. mucilaginos, E. miricola, M. paraoxydans |
| 16 Sputum CF | P. aeruginosa, S. aureus, E. coli, S. anginosus, B. sonorensis | P. aeruginosa, S. aureus, E. coli, S. anginosus, B. sonorensis |
| 17 Sputum CF | P. aeruginosa, S. aureus, E. coli, B. cereus | P. aeruginosa, S. aureus, E. coli, B. cereus |
| 18 BAL HAP | K. pneumoniae, R. dentocariosa, A. ursingii, B. pumilus | K. pneumoniae, R. dentocariosa, A. ursingii, B. pumilus |
| 19 BAL CAP | H. influenzae, A. suis, E. corrodens, A. oris | H. influenzae, A. suis, E. corrodens, A. oris |
| 20 BAL COPD | K. pneumoniae, H. influenza, B. obstructivus | K. pneumoniae, H. influenza, B. obstructivus |

Bacteria from all cystic fibrosis patient samples were plated on LB medium as well as cultivated on *Burkholderia cepacia* selective agar, chocolate agar, and CHROMagar Staph aureus medium.

Already after 4 h, direct plating on TGV media allowed to cultivate mixed bacterial communities in 19 of 20 clinical specimens (95%). The increase of the culturing time to 24 h did not increase the diversity of cultured bacteria. Under the same conditions, no mixed communities (0/100; 0%) were observed during exposure to LB media after 4 h. Subsequent culturing for up to 24 h allowed to identify polymicrobial communities only in 5 out of 20 samples (25%).

Next, we determined the overall gain of identified microbial diversity that gave growth on TGV vs standard media, demonstrating that even after 4 h of culturing, TGV uncovered a more diverse
set of microorganisms from the biological specimens compared with that revealed by the standard medium after 24 h of culturing (Fig. 3).

**Figure 3.** Comparison of the richness of bacteria that gave growth on TGV medium (after 4 h of culturing) compared with that of bacteria that gave growth (after 24 h) on LB agar (LB medium, *Burkholderia cepacia*-selective agar, chocolate agar, CHROMagar Staph aureus medium). Richness values for bio samples in two types of media are represented on a dot plot, displaying the distribution of numerical variables where each dot represents a value. The height of the column of dots represents the frequency for that value. The package ‘ggplot2’ within R (version 3.4.1) was used.

Notably, in the majority of specimens grown on TGV, we identified more than one well-known pathogen of respiratory tract infections, whereas the standard method allowed the identification of one and, only sometimes, two pathogens. The highest microbial diversity was observed in sputum of the patients with cystic fibrosis (CF) – a disease that is known to be characterized by a particularly complex, mixed lung microbiome (68). For example, from some tissue specimens, we isolated *P. aeruginosa, Staphylococcus haemolyticus, A. baumannii, Achromobacter xylosoxidans,* and *Burkholderia thailandensis* with TGV medium. Each of these microorganisms has been shown to be associated with lung infections in CF, whereas the standard method identified only the dominant *P. aeruginosa* (69-71).

The ability of TGV to enable growth of fastidious species is illustrated by the isolation of *Streptococcus milleri* from CF patient #10. This bacterium was only recently associated with pulmonary complications in CF because previously, *S. milleri* could not be cultured on standard laboratory media (72, 73). Another notable example was the identification with TGV of *K. pneumoniae, Rothia dentocariosa, Acinetobacter ursingii* and *Bacillus pumilus*, in sample #18 from the patient with hospital-acquired pneumonia (74). Each of these species had been shown previously to be associated with human infections. However, under the same conditions, the standard method identified only *K. pneumoniae*. A similar trend was noted for all other tested specimens from cases of other respiratory...
diseases whereby TGV enabled identification of a wider range of known respiratory pathogens compared to that revealed by the standard method. Notably, by using TGV medium, we identified two previously unknown bacterial species Chryseobacterium mucoviscidosis sp. nov. and Bacillus obstructivus sp. nov. (75, 76). These bacteria have not been identified by MALDI-TOF, as they had very low similarity to known species, and their further whole genome sequencing proved that they were previously unknown bacterial species highly enriched in genes encoding pathogenic and antibiotic resistance factors.

3.3 Antibiotic selection in monomicrobial cultures using AtbFinder

The performance of the AtbFinder for direct selection of 10 different antibiotics prescribed for the treatment of respiratory infections caused by Gram-positive or Gram-negative bacteria was evaluated in a total of 122 monobacterial cultures after 4 h and 24 h of culturing. Cultures of 3 out of 122 strains (S. pneumoniae VT-SP-14, S. maltophilia VT-CFSM-4, and A. baumannii ATCC 17978) were excluded from the experiment due to the lack of growth in control wells after 4 h, leaving 1,190 runs in total for analysis (119 bacterial species tested against 10 antibiotics; 1 run = each antibiotic tested against one bacterial strain). For the tested 119 strains, correct antibiotic selection, as gauged by the results of conventional AST, was achieved after 4 h in 1,177 of 1,190 runs (98.9%). In rare cases, false-positive and false-negative results were obtained. The overall sensitivity, specificity, PPV, and NPV were 99.6%, 98.1%, 98.5%, and 99.4%, respectively (Tables 2 and Supplementary table 2).

| Species       | N true positive 4 h | N true negative 4 h | N false positive 4 h | N false negative 4 h | Sensitivity (%) 4 h | Specificity (%) 4 h | PPV (%) 4 h | NPV (%) 4 h |
|---------------|---------------------|---------------------|----------------------|----------------------|---------------------|---------------------|-------------|-------------|
| S. aureus     | 134                 | 134                 | 84                   | 84                   | 99,3                | 99,3                | 98,8        | 99,3        |
| S. pneumoniae | 12                  | 16                  | 18                   | 24                   | 0                   | 1                   | 100         | 100         |
| S. epidermidis| 16                  | 17                  | 23                   | 23                   | 0                   | 0                   | 100         | 100         |
| S. pyogenes   | 10                  | 10                  | 30                   | 30                   | 0                   | 0                   | 100         | 100         |
| Microorganism            | NPV  | PPV  | NPV  | PPV  | NPV  | PPV  | NPV  | PPV  | NPV  | PPV  | NPV  | PPV  | NPV  | PPV  |
|-------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| E. faecalis             | 27   | 27   | 27   | 27   | 22   | 22   | 1    | 1    | 0    | 0    | 100  | 100  | 95.6 | 96.4 |
| B. cereus               | 17   | 17   | 23   | 23   | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| Pseudomonas VT400       | 5    | 5    | 4    | 4    | 1    | 1    | 0    | 0    | 100  | 80   | 88   | 83.3 | 83.3 | 100  |
| B. respiratorii VT1664  | 3    | 3    | 7    | 7    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| E. coli                 | 70   | 71   | 78   | 78   | 2    | 1    | 0    | 0    | 100  | 97.5 | 98.8 | 97.2 | 97.2 | 100  |
| A. baumannii            | 8    | 16   | 1    | 4    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| S. maltophilia          | 19   | 28   | 10   | 11   | 1    | 1    | 0    | 0    | 100  | 90.1 | 91.6 | 95   | 95   | 100  |
| K. pneumoniae           | 51   | 51   | 47   | 47   | 1    | 1    | 1    | 1    | 100  | 98.1 | 98.1 | 97.9 | 97.9 | 98.1 |
| P. vulgaris             | 18   | 18   | 22   | 22   | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| P. mirabilis            | 22   | 22   | 28   | 28   | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| B. influenzae           | 2    | 2    | 8    | 8    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| K. oxytoca              | 6    | 6    | 4    | 4    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| R. mucilaginosa         | 4    | 4    | 6    | 6    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| M. catharrhalis         | 4    | 4    | 6    | 6    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| P. aeruginosa           | 122  | 122  | 35   | 35   | 2    | 2    | 1    | 1    | 99.2 | 99.2 | 94.6 | 94.6 | 98.4 | 97.2 |
| B. cenocepacia          | 53   | 53   | 7    | 7    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| E. cloacae complex      | 31   | 31   | 29   | 29   | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| A. xylosoxidans         | 16   | 16   | 4    | 4    | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| S. marcescens           | 14   | 14   | 16   | 16   | 0    | 0    | 0    | 0    | 100  | 100  | 100  | 100  | 100  | 100  |
| Gram-positive bacteria   | 403  | 408  | 259  | 265  | 6    | 5    | 2    | 2    | 99.9 | 99.9 | 96.8 | 97.2 | 97.4 | 99.6 |
| Gram-negative bacteria   | 437  | 455  | 295  | 298  | 14   | 14   | 2    | 2    | 99.8 | 99.8 | 98.6 | 98.8 | 99.2 | 99.7 |

NPV, negative predictive value; PPV, positive predictive value.
After 24 h of culturing, we performed 1,220 runs in total, as all bacteria at this time gave growth on TGV control antibiotic-free medium. By 18 h, all microbial strains gave growth in control wells. Correct antibiotic selection was achieved at 1,209 of 1,220 runs (99.1%). The values of analyzed parameters after 24 h of culturing were marginally higher than those achieved after 4 h (sensitivity, 99.6%; specificity, 98.5%; PPV, 98.8%; and NPV, 99.4%; Tables 2, Supplementary table 3). Notably, there was no difference in the overall ability to detect Gram-positive and Gram-negative bacteria.

Next, we determined CA after 4 and 24 h of culturing for each antibiotic. After 4 h, the overall CA for all antibiotics used was 98.9% (1,177/1,190, 10 very major errors, 3 major errors). The rate of very major errors was 1.5% (10 very major errors/666 resistance outcomes), and the rate of major errors was 0.6% (3 major errors/512 susceptibility outcomes). The highest CA values were observed for levofloxacin, vancomycin (absolute agreement, 100%), followed by those for aztreonam, gentamicin, linezolid, piperacillin/tazobactam (for all: 118/119; 99.2%), amikacin, azithromycin, cefepime (for all: 117/119; 98.3%), and meropenem (116/119; 97.4%) (Table 3).

Table 3. Category agreement of antibiotic sensitivity results of the AtbFinder method with those obtained by the standard method after 4 and 24 h of culturing.

| Antibiotic          | Category agreement: No of correct identifications/total No of observations (%) | Very major (false-positive) | Major (false-negative) |
|---------------------|--------------------------------------------------------------------------------|------------------------------|------------------------|
|                     | No of 4h                       | 24h                          |                        |                        |
| Piperacillin-tazobactam | 118/119 (99,2)                  | 122/122 (100)                 | 1                      | 0                      | 0                      | 0                      |
| Meropenem           | 116/119 (97,4)                  | 119/122 (97,5)                | 2                      | 2                      | 1                      | 1                      |
| Levofloxacin        | 119/119 (100)                   | 122/122 (100)                 | 0                      | 0                      | 0                      | 0                      |
| Aztreonam           | 118/119 (99,2)                  | 121/122 (99,2)                | 1                      | 1                      | 0                      | 0                      |
| Gentamicin          | 118/119 (99,2)                  | 121/122 (99,2)                | 0                      | 0                      | 1                      | 1                      |
| Amikacin            | 117/119 (98,3)                  | 120/122 (98,3)                | 2                      | 2                      | 0                      | 0                      |
| Azithromycin        | 117/119 (98,3)                  | 121/122 (99,2)                | 2                      | 1                      | 0                      | 0                      |
| Vancomycin          | 119/119 (100)                   | 122/122 (100)                 | 0                      | 0                      | 0                      | 0                      |
| Cefepime            | 117/119 (98,3)                  | 120/122 (98,3)                | 2                      | 2                      | 0                      | 0                      |
| Linezolid           | 118/119 (99,2)                  | 121/122 (99,2)                | 0                      | 0                      | 1                      | 1                      |
| Overall performance | 1177/1190 (98,9)                | 1209/1220 (99,1)              |                         |                        |                        |                        |

Bacterial cultures included monomicrobial cultures of Staphylococcus aureus (n = 22), Streptococcus pneumoniae (n = 4), Streptococcus pyogenes (n = 2), Enterococcus faecalis (n = 5), Bacillus cereus (n = 4), Paenibacillus VT400 (n = 1), Bacillus respiratorii VT-16-64 (n = 1) Escherichia coli (n = 15), Acinetobacter baumannii (n = 2), Stenotrophomonas maltophilia (n = 4), Klebsiella pneumoniae (n = 10), Proteus vulgaris (n = 4), Proteus mirabilis (n = 5), Haemophilus influenzae (n = 1), Klebsiella oxytoca (n = 1), Rothia mucilaginosa (n = 1), Moraxella catharrhalis (n = 1) Pseudomonas
aeruginosa (n = 16), Burkholderia cenocepacia (n = 6), Enterobacter cloacae complex (n = 6), Achromobacter xylosoxidans (n = 2), Serratia marcescens (n = 3).

CA values for the AtbFinder were even higher when the period of culturing was extended. The overall CA for all antibiotics after 24 h of cultivation was 99.1% (1,209/1,220) with 8 very major errors and 3 major errors. The rate of very major errors was 1.2% (8 very major errors/688 resistance results), and the rate of major errors was 0.6% (3 major errors/521 susceptibility results). CA values became nominally higher for piperacillin/tazobactam and azithromycin. Thus, after 24 h of culturing, the absolute CA was observed for piperacillin/tazobactam, levofloxacin, and vancomycin with no errors detected (100%). Slightly lower, but nonetheless very high CA values were noted for aztreonam, azithromycin, gentamicin, linezolid (for all: 121/122; 99.2%), amikacin, cefepime (for all: 120/122; 98.3%), and meropenem (119/122; 97.5%) (Table 3).

At both time points tested, the level of major errors was very low, indicating that antibiotic-sensitive isolates did not grow on TGV medium with antibiotics added at chosen concentrations. In general, there was no discernible pattern of the errors that could be explained by the nature of microorganisms or antibiotics tested: AST errors occurred in various species and with various drugs. CA values were not statistically different between the antibiotics used.

3.4 Antibiotic selection in polymicrobial cultures using AtbFinder

When developing AtbFinder, we assumed that the antibiotic response of mixed cultures from the site of infection grown on TGV may be different compared to the antibiotic response of bacteria identified with the standard AST methods. Because the antibiotic resistance profile of the principal pathogen identified with a standard AST does not properly reflect the collective antibiotic resistance, this circumstance can lead to a false-negative antibiotic selection.
**Figure 4**

### Table A

|   | Clinical specimen | Diagnosis  | AntiFinder | Standard AST |
|---|-------------------|------------|------------|--------------|
| 1 | BAL               | CAAP       | KA, SA, EC, EF, PR | KP           |
| 2 | BAL               | Pneumonia  | SA, SP     | SA           |
| 3 | BAL               | Pneumonia  | SA, EC, PA | PA           |
| 4 | Sputum            | CF         | PA, AX, EA | PA           |
| 5 | Sputum            | CF         | SM, EC, BS, PA | PA          |
| 6 | Sputum            | CF         | PA, SHAB, AX, BT | PA         |
| 7 | Sputum            | CF         | AX, RM, E,M, MP | AX       |
| 8 | Sputum            | CF         | PA, SA, EC, SAN, IB | PA   |
| 9 | BAL               | HAP        | KP, RD, AU, BP | KP         |
| 10| BAL               | Exacerbation of COPD | KP, H, BO | KP           |

### Diagrams B, D, C, E

The diagrams illustrate various patterns and data comparisons, possibly related to the clinical specimen and diagnosis data presented in Table A. The diagrams may show trends or results from the AntiFinder and Standard AST methods.
Selection of antibiotics for polymicrobial biological samples with AtbFinder compared with that achieved with a standard AST method.

Antibiotics used: amikacin (AMK), azithromycin (AZM), aztreonam (ATM), cefepime (CEF), gentamycin (GEN), levofloxacin (LVX), linezolid (LZD), meropenem (MEM), pipercillin-tazobactam (TZP) vancomycin (VAN).

(A) Comparison of the diversity of bacteria grown on TGV of AtbFinder (for 4 h) and on the standard medium used by AST (for 24 h).

A.baumannii (AB), A. xylosoxidans (AX), A. ursingii (AU), Bacillus spp (BS), Bacillus obstructivus (BO), B.pumilus (BP), B.sonorensis (BS), B.thailadensis (BT), Enterobacter cloacae (EntC), Enterococcus faecalis (EF), Elizabethkingia miricola (EM), Escherichia coli (EC), Haemophilus influenzae (HI), K.pneumoniae (KP), Microbacterium paraoxydans (MP), Proteus spp (PR), R.mucilaginosa (RM), R. dentocariosa (RD), S.anginosus (SAN), S.aureus (SA), S.maltophilia (SM), S.heamolyticus (SH), S.pneumoniae (SP).

BAL - Bronchoalveolar lavage, CF – cystic fibrosis, CAP - community-acquired pneumonia, HAP - Hospital-acquired pneumonia, COPD - Chronic obstructive pulmonary disease

(B) Antibiotic efficacy identified with AtbFinder. (C) Antibiotic efficacy identified by the standard AST method. Red circles in (B) and (C) represent resistant determinations (“ineffective” antibiotics) and green circles represent susceptible determinations (“effective” antibiotics).

(D) Analysis of the discrepancies in the efficacy of antibiotics between the AtbFinder and standard AST methods. Red squares depict antibiotics that according to AtbFinder were predicted to be “ineffective” for specific biosamples but deemed “effective” by the standard AST method.

(E) Bacterial cultures from the discrepant cases outlined in that were suggested as ineffective against to be resistant to certain antibiotics with AtbFinder, and thus experienced growth in the wells with in the presence of that certain antibiotic, but were deemed “effective” against identified pathogens by the standard AST method were subcultured from the wells of AtFinder and identified. Bacteria marked with red letters were suggested to be the principal pathogen by the standard AST method and, when grown under the conditions modulated according to the standard AST method, were killed by this specific antibiotic (see Fig 4C). Bacteria marked in blue were not suggested to be the primary pathogen by the standard AST method.

To test this assumption, we used 10 randomly selected samples from the cases of respiratory infections tested before in this study and analyzed particularities of antibiotic selection with AtbFinder (after growth for 4 h) (Fig. 4B) and culture-based gold standard method (microdilution) (Fig. 4C). Notably, along with a broader diversity of bacteria from the specimens grown on TGV of AtbFinder compared to the microbial diversity on LB agar used in a standard method (Fig 4A), we identified a discrepancy between the antibiotics suggested as effective by the AtbFinder and standard methods (Fig. 4D). When the 10 biosamples were each tested against 10 antibiotics (100 evaluations in total), we found 18 cases of discrepancy in the conclusion regarding antibiotic efficacy.
In these cases, antibiotics were deemed as effective by the standard AST, but they were suggested to be ineffective by AtbFinder, as the bacteria from those samples could grow in the wells of AtbFinder with those antibiotics (red squares in Fig. 4 D). Then, to identify the bacteria that grew in the wells of AtbFinder with these antibiotics, we performed their follow-up subculturing. As illustrated in Figure 4E, we were able to isolate bacteria that according to standard AST were suggested as the principal pathogen from 11 out of the total 18 discrepancy wells.

That result meant that in 11 out of 100 total antibiotic efficacy evaluations (11%) when a mixed bacterial community grew on AtbFinder, the principal pathogens resisted the antibiotics selected as effective in monobacterial cultures of these pathogens in conditions of the standard AST. Therefore, 11% of discrepancy cases potentially represents the rate of false positive results of the standard AST method and could mislead the selection of antibiotics that might be ineffective in certain patient. Most likely this happened because complicated polymicrobial interactions at the site of infection that resulted in the higher resistance of bacteria, including the principal pathogen, were not adequately simulated by the standard method that utilizes monobacterial culture growth. However, such interactions could be modeled well with the AtbFinder system.

Notably, in some cases, narrow-spectrum antibiotics added to AtbFinder, active only against Gram-positive or Gram-negative bacteria inhibited the growth of mixed bacterial communities formed by both Gram-positive and Gram-negative bacteria. For example, aztreonam was effective against mixed communities formed not only by the Gram-negative P. aeruginosa, but also by the Gram-positive S. aureus (in probe 3) (Fig. 4A). Furthermore, vancomycin, known to be effective solely against Gram-positive bacteria, was effective against mixed communities comprised of not only Gram-positive bacteria, but also P. aeruginosa, E. coli, and other Gram-negative microorganisms (in probes 5, 8), indicating complicated interspecies interactions in polymicrobial communities when one bacteria is required to support the growth of other microorganisms (Fig 4A). This is in agreement with some recently published data that have shown that the overall response to antibiotics of a mixed community is sometimes the opposite to that of individual bacteria (77).

4. Discussion

New diagnostic methods for the selection of antibiotics for tailored empirical therapy and for the change of antibiotic therapy that failed in immunocompromised patients are urgently needed (78). The availability of rapid and accurate methods of antibiotic selection for non-bloodstream infections, such as lung, urinary tract, skin, and soft tissue infections, would have a great impact on the disease outcome, length of hospital stay, possible complications, and spread of antibiotic resistance (79).
Our present experiments evaluated for the first time the performance of the novel AtbFinder system providing culture-based antibiotic selection within a short, 4 h period based on the novel principle to select antibiotics effective against polymicrobial communities from pathological material (Fig. 5).

Figure 5.

AtbFinder principle of operation and performance. Illustrated schematic of the AtbFinder performance protocol developed for different biosamples. (1) A biosample, which can be optionally diluted with sterile water, is plated onto the wells of 12–96-well AtbFinder plates. In the 12-well plates used in this study, ten “testing wells” contained TGV nutrient medium with antibiotics (one antibiotic per well) selected as per current therapeutic guidelines and added to the medium at concentrations clinically achievable at the site of infection. Two “control wells” contained antibiotic-free TGV medium. (2) Plate reading is performed following sampling and incubation at 37 °C for 4 h. The presence of microbial growth is identified with the naked eye and can be confirmed with a stereoscopic microscope. Microbial growth in any “testing well” means that in the pathological material there are microorganisms resistant to the antibiotic that has been added to the nutrient medium in this well. This antibiotic is categorized as “ineffective”. The absence of bacterial growth
in the well means that the antibiotic present in the well leads to a complete killing or inhibits the growth of all bacteria in the biospecimens and such an antibiotic is categorized as “effective”.

The AtbFinder method can be used for initial tailored empirical therapy and for the selection of an appropriate antibiotic to those patients who have not responded to the previous therapy and require change of antimicrobial treatment strategy. Our original hypothesis that the use of the AtbFinder system would provide a rapid and accurate selection of antibiotics for both monobacterial or polybacterial infections sampled directly from clinical specimens, was found to be confirmed experimentally. AtbFinder system allowed faster growth of monobacterial cultures compared with that achieved by the standard method used in clinical diagnostics and demonstrated an increased richness with higher ACE and Chao 1 indices for bacteria that gave growth within 4 h on AtbFinder medium than those recorded for bacteria grown on LB agar or Columbia agar (Fig. 2).

Our study also revealed that AtbFinder system provided accurate antibiotic selection compared to that achieved by the standard of care, with antibiotics added to the media at a concentration that can be achieved at the site of infection, with results being available already after 4 h of culturing. If compared with the standard method that involves the isolation of pure bacterial cultures prior to AST, the AtbFinder system was faster by more than 32 h. The antibiotic selection was highly accurate already within 4 h (sensitivity, 99.6%; specificity, 98.1%; PPV, 98.5%; NPV, 99.4%, and CA, 98.9%); with no discernable bias in the error pattern toward Gram-positive or Gram-negative bacteria or toward a particular antibiotic class. Furthermore, the increase of culturing time from 4 h to 24 h did not significantly change the accuracy of the AtbFinder method performance, indicating that accurate results can be obtained after just several hours of culturing.

In the current study, TGV medium supported growth of a significantly more diverse set of bacteria from biological samples even after 4 h of culturing than the standard medium, broadly used in microbiological laboratories, after 24 h of culturing. Thus, AtbFinder system allowed identification of polymicrobial cultures in 19 out of 20 samples after 4 h of culturing. This was in agreement with previous reports that emphasized the polymicrobial nature of the majority of respiratory tract infections (13). Under the same conditions, the latter approach detected polymicrobial cultures in only 5 out of 20 samples. In this study, the standard method failed to detect not only some isolated commensal bacteria, but also well-known causative agents of respiratory infections. For example, AtbFinder allowed growth of *S. aureus*, *H. influenzae*, *E. miricola*, *A. baumannii*, *A. xylosoxidans*, and other well-known respiratory tract pathogens in samples from CF and chronic obstructive pulmonary disease. These microorganisms have been shown to cause recurrent respiratory infections but are completely overlooked by standard of care diagnostics.

In the current study, the AtbFinder system enabled growth of different complex mixtures of bacteria without a limit to the number of species that could be isolated. This finding is of primary importance due to two considerations. First, the presence of polymicrobial infections is one of the reasons for the inappropriate antibiotic selection and mortality of high-risk patients. The elimination of the dominant
strains leads to the re-growth of other bacteria at the site of the infection unaffected by the initial antibiotic treatment, which may lead to disease progression and complications, e.g., due to the lack of sufficiently strong immune response. Moreover, as it has been shown before, some bacteria that are considered nonpathogenic in the lungs of non-immunosuppressed subjects may be pathogenic in immunosuppressed hosts (80, 81). This is why, for some bloodstream infections, sterilization is widely used, particularly in the patients with impaired immune response. Therefore, the fact that AtbFinder system reliably detects both major and minor bacterial pathogens within the site of infection makes it promising for the use in immunocompromised patients. Second, our assessment of antibiotic sensitivity within polymicrobial communities showed that in some cases, antibiotics selected with the standard method did not eliminate even the dominant bacteria in mixed microbial communities. Such false-negative data might result in the selection of ineffective antibiotics and therapy failure (82). The reason for false-positive results generated by the gold standard method may be because this method enables growth of monobacterial cultures but does not take into consideration higher tolerance to antibiotics of bacteria within mixed communities (15). However, “real life” infections are predominantly polymicrobial by nature (10). The resulting survival of the lead pathogen leads to its re-growth and therapy failure. According to our in vitro data, AtbFinder is less prone to such limitations.

Furthermore, the use of the AtbFinder system for the treatment of polybacterial infections allowed selection of not only broad spectrum but also narrow spectrum antibiotics, confirming the presence of complexed interspecies interactions in mixed bacterial communities.

Notably, by using AtbFinder, we have isolated previously unknown bacterial species *Chryseobacterium mucoviscidosis* sp. nov. and *Bacillus obstructivus* sp. nov. that possessed several typical virulence factors, such as hemolysins and others, which are found in other respiratory pathogens (76, 76 83). Moreover, in these bacteria, we identified several antibiotic resistance genes that once found in endospore-forming *Bacillus* spp. are of concern because of the possible spread of antibiotic resistance among sporobiota members (84). The identification of previously unknown bacteria as well as some fastidious species, such as *S. milleri*, indicates that the developed TGV medium provides unique growth factors and cultivation environment that are not achievable with the standard media (19, 85).

The use of the AtbFinder system enables to quickly select antibiotics that are effective for the treatment of each particular condition (i.e., those that kill or inhibit bacterial growth of all microorganisms present in the clinical specimen) without the need to identify precisely the causative agents of the infection or to determine MICs. Importantly, although the AtbFinder test does not allow immediate identification of bacteria on the species level, bacterial cultures that gave growth on TGV medium can be isolated and subsequently identified by using culture-based techniques and any other standard methods for the study of bacteria.
AtbFinder system has all benefits of phenotypic culture-based methods, but is 30–54 h faster than standard culture-based diagnostics that requires time-consuming isolation of pure bacterial cultures. Even compared with direct AST, the AtbFinder method allows antibiotic selection on a much shorter timescale (60). Like direct AST, AtbFinder system enables direct sampling of biological specimens without the need for culturing or time-consuming sample processing. Furthermore, the AtbFinder method can indicate the suitable antibiotic in only 4 h, whereas direct AST requires 18–36 h (and that is why direct AST is not applicable for tailoring empirical antibiotic therapy) (86).

Despite being as fast as some of the molecular biology methods, AtbFinder system lacks main disadvantages of molecular methods based on next-generation sequencing and 16S RNA sequencing, such as overestimation of antimicrobial resistance and inability to inform on antimicrobial susceptibility (37, 38). Moreover, there is no need for either any specific equipment, except a thermostat, or for highly trained personnel, because the presence or absence of bacterial growth can be identified by the personnel with basic laboratory skills. In this study, we used AtbFinder system with a set of antibiotics used for the treatment of respiratory infections. However, it can easily be adjusted for the diagnosis of the infections of other parts of the body, such as urinary tract, skin, or soft tissues, by including the antibiotics used for the therapy of these infections in TGV medium. Moreover, it can be used for the cultivation of bacteria with different oxygen requirements. The presence of bacterial growth was analyzed with naked eye and stereoscopic microscopy, but a more sophisticated device for visual monitoring can be used to increase the analysis accuracy. We believe that AtbFinder system may become a novel and valuable tool in improving antibiotic selection, with as little as 4 h turnaround time. In terms of the possible laboratory implementation, AtbFinder dramatically shortens the testing routine by allowing appropriate antibiotic selection on the same day. Therefore, AtbFinder enables more effective antibiotic selection for the targeted empirical therapy and accurate antibiotic replacement, especially in high-risk immunocompromised patients. Future studies will be necessary to investigate clinical efficacy of the AtbFinder system and the clinical impact of its use alone and as an auxiliary method for standard diagnostics.

5. Conclusions

This section is not mandatory, but can be added to the manuscript if the discussion is unusually long or complex.

**Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1,

Supplementary Table S1. Individual patterns of resistance to antibiotics.

Supplementary Table S2. Results of antimicrobial susceptibility testing by using the AtbFinder system (4 h culturing) and standard method (24 h culturing) for 119 Gram-positive and Gram-negative pathogens.

Supplementary Table S3. Results of antimicrobial susceptibility testing by using the AtbFinder system and standard method for 122 Gram-positive and Gram-negative pathogens after 24 h of culturing.
**Author Contributions:** GT and VT designed the experiments. GT performed the experiments and supervised data analysis. VT and GT analyzed the data and wrote the manuscript.

**Funding:** Please add: This research received no external funding”

**Acknowledgments:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. We would like to thank Gregory Andronica for valuable input.

**Conflicts of Interest:** VT and GT have applied for a patent for the TGV medium.
References

1. Leekha S, Terrell CL, Edson RS. 2011. General principles of antimicrobial therapy. In Mayo Clinic Proceedings 86:156-167.
2. Postma, D.F., Van Werkhoven, C.H., Van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., Boersma, W.G., Compaijen, C.J., Van Der Wall, E., Prins, J.M. and Oosterheert, J.J. 2015. Antibiotic treatment strategies for community-acquired pneumonia in adults. New England Journal of Medicine 372: 1312-1323.
3. Mettler J, Simcock M, Sendi P, Widmer AF, Bingisser R, Battegay M, Fluckiger U, Bassetti S. 2007. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC infectious diseases 7:21.
4. Braykov NP, Morgan DJ, Schweizer ML, Uslan DZ, Kelesidis T, Weisenberg SA, Johannsson B, Young H, Cantey J, Srinivasan A, Perecevich E, 2014. Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. The Lancet Infectious Diseases 14:1220-1227.
5. Reller LB, Weinstein M, Jorgensen JH, Ferraro MJ. 2009. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clinical infectious diseases 49:1749-55.
6. Peters BM, Jabra-Rizk MA, Graeme AO, Costerton JW, Shirtliff M. 2012 Polymicrobial interactions: impact on pathogenesis and human disease. Clinical microbiology reviews 25:193-213.
7. Cillóniz C, Ewig S, Ferrer M, Polverino E, Gabarrús A, de la Bellacasa JP, Mensa J, Torres A. 2011. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Critical Care 15:R209.
8. Shanmugam P, Jeya M. 2013 The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. Journal of clinical and diagnostic research 7:441.
9. Mayrand D. 1985. Virulence promotion by mixed bacterial infections. In The pathogenesis of bacterial infections 281-292. Springer, Berlin, Heidelberg.
10. Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, Saiman L. 2016. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 149:390-400.
11. Fishman JA. 2011. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transplantation 2011 17:S34-7.
21. Jørgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P, Høiby N, Koch C. 2003. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatric pulmonology 36:439-46.

22. Del Castillo E, Meier R, Chung M, Koestler DC, Chen T, Paster BJ, Charpentier K, Kelsey KT, Izard J, Michaud DS. 2018. The Microbiomes of Pancreatic and Duodenal Tissue Overlap and are Highly Subject Specific but Differ between Pancreatic Cancer and Non-Cancer Subjects. Cancer Epidemiology and Prevention Biomarkers 1:cebp-0542.

23. Tetz V, Tetz G. 2017. Draft genome sequence of the uropathogenic Herbaspirillum frisingense strain ureolytics. VT-16-41. Genome Announcements 5: e00279–e00217.

24. Wang JT, Fang CT, Hsueh PR, Chang SC, Luh KT. 200. Spontaneous bacterial empyema caused by Aeromonas veronii biotype sobria. Diagnostic microbiology and infectious disease 37:271-3.

25. Liu W, Røder HL, Madsen JS, Bjarnsholt T, Sørensen SJ, Burmølle M. 2016. Interspecific bacterial interactions are reflected in multispecies biofilm spatial organization. Frontiers in microbiology 7:1366.

26. Vartoukian SR, Palmer RM, Wade WG. 2010. Strategies for culture of ‘unculturable’ bacteria. FEMS microbiology letters 309:1-7.

27. Browne HP, Forster SC, Kumar N, Neville BA, Stares MD, Goulding D, Lawley TD. 2016. Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation. Nature 533:543.

28. Kaeberlein T, Lewis K, Epstein SS. 2002. Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science 296:1127-9.

29. Bertelli C, Greub G. 2013. Rapid bacterial genome sequencing: methods and applications in clinical microbiology. Clinical Microbiology and Infection, 19: 803-813.

30. Price LB, Liu CM, Melendez JH, Frankel YM, Engelbhalder A, Aziz M, Bowers K, Rattray R, Ravel J, Kingsley C, Keim PS, Lazarus JS, Zenilman JM. 2009. Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota. PloS one 4: e6462.

31. Pulido MR, García-Quintanilla M, Martin-Peña R, Cisneros JM, McConnell MJ. 2013. Progress on the development of rapid methods for antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy 68:2710-2717.

32. Charnot-Katsikas A, Tesic V, Love N, Hil, B, Bethel C, Boonlayangoor S, Beavis KG. 2017. Use of Accelerate Pheno™ system for identification and antimicrobial susceptibility testing (ID/AST) of pathogens in positive blood cultures and impact on time to results and workflow. Journal of clinical microbiology 2017. JCM-01166.

33. Mardis ER. 2008. The impact of next-generation sequencing technology on genetics. Trends in genetics, 24:133-141.

34. Davenport M, Mach KE, Shortliffe LMD, Banaei N, Wang TH, Liao JC. 2017. New and developing diagnostic technologies for urinary tract infections. Nature Reviews Urology 14:296.

35. Ellington, M. J., Ekelund, O., Aarestrup, F. M., Canton, R., Doumith, M., Giske, C. H.Grundman, H.Hasman. Holden M.T.G., Hopkins KL, Iredell J, Kahlmeter J, Köser J, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Woodford N. 2017. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clinical microbiology and infection 23:2-22.

36. Maurer FP, Christner M, Hentschke M, Rohde H. 2017. Advances in rapid identification and susceptibility testing of bacteria in the clinical microbiology laboratory: implications for patient care and antimicrobial stewardship programs. Infectious disease reports 9.

37. Tetz G, Tetz V. 2015. Complete genome sequence of Bacilli bacterium strain VT-13-104 isolated from the intestine of a patient with duodenal cancer. Genome Announcements 3:e00705–15.

38. Wang L, Lee F, Tai C, Kasai H. 2007. Comparison of gyrB gene sequences, 16S rRNA gene sequences and DNA–DNA hybridization in the Bacillus subtilis group. International Journal Systematic Evolutionary Microbiology 57:1846–50.

39. Su M, Satola SW, Road TD. 2018. Genome-based prediction of bacterial antibiotic resistance. Journal of clinical microbiology JCM-01405.
40. Sundsfjord A, Simonsen GS, Haldorsen BC, Haavegall SO, Littauer P, Dahl KH. 2004. Genetic methods for detection of antimicrobial resistance. Apmis 112:815-37.

41. Martineau F, Picard FJ, Lancas N, Ménard C, Roy PH, Ouellette M, Bergeron MG. 2000. Correlation between the Resistance Genotype Determined by Multiplex PCR Assays and the Antibiotic Susceptibility Patterns of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial agents and chemotherapy 44:231-8.

42. Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. 2017. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clinical Microbiology and Infection 23:154-60.

43. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American journal of respiratory and critical care medicine 2005 171:388.

44. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File Jr TM, Musher DM, Niederman MS, Torres A. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical infectious diseases 44:527-72.

45. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’grady NP, Bartlett JG, Carratalà J, El Solh AA. 2016. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases 63:e61-111.

46. Bergogne-Bérézin E. 2004. Pharmacodynamics of antibiotics in the respiratory tree. Expert opinion on pharmacotherapy 5:15-23.

47. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 25:73-82.

48. Ramsey C, MacGowan AP. 2016. A review of the pharmacokinetics and pharmacodynamics of aztreonam. Journal of Antimicrobial Chemotherapy 71:2704-12.

49. Beam TR, Galask RP, Friedhoff LT, Platt TB, Leitz MA. 1986. Aztreonam concentrations in human tissues obtained during thoracic and gynecologic surgery. Antimicrobial agents and chemotherapy 30:505-7.

50. Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Critical care medicine 31:210 2-6.

51. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. 2005. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128:545-52.

52. Rovdold KA, Danziger LH, Gottfried MH. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrobial agents and chemotherapy 47:2450-7.

53. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. 2003. Intrapulmonary penetration of linezolid. Journal of Antimicrobial Chemotherapy 51:1431-4.

54. Conte JE, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrobial agents and chemotherapy 46:1475-80.

55. Byl B, Jacobs F, Roucloux I, de Franquen P, Cappello M, Thys JP. 1999. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrobial agents and chemotherapy 43:681-2.

56. Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B. 2004. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive care medicine 30:976-9.

57. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccoli G, Malena M, Franchini C, Concia E. 1996. Penetration of vancomycin into human lung tissue. Journal of Antimicrobial Chemotherapy. 38:865-9.

58. Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva J-A, Garbinio J, Yan JL, Aram J, Capparella MR, Conte U, Schlamm H, Swanson R, Herbrecht R. 2017. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. Journal of Antimicrobial Chemotherapy 72:2368-2377.
59. Ishizaki T, Hieda J, Bratescu MA, Saito N, Takai O. 2009. Biomimetic materials processing. In Nanostructured Thin Films International Society for Optics and Photonics 7404: 74040M.
60. Kageyama A, Benno Y. 2001. Rapid detection of human fecal Eubacterium species and related genera by nested PCR method. Microbiology and immunology 45:315-8.
61. Wilson DA, Reischl U, Hall GS, Procop GW. 2007. Use of partial 16S rRNA gene sequencing for identification of Legionella pneumophila and non-pneumophila Legionella spp. Journal of clinical microbiology 45:257-8.
62. Chun J, Lee JH, Jung Y, Kim M, Kim S, Kim BK, Lim YW. 2007. EzTaxon: a web-based tool for the identification of prokaryotes based on 16S ribosomal RNA gene sequences. International journal of systematic and evolutionary microbiology 57:2259-61.
63. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
64. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 9th ed, M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
65. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26 ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
66. Parikh R, Mathai A, Parikh S, Sekhar GC, Thomas R. 2008. Understanding and using sensitivity, specificity and predictive values. Indian journal of ophthalmology. 56:45.
67. R Core Team. 2017. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
68. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E, Sime-Ngando T. 2012. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community—implications for therapeutic management. PloS one 7:e36313.
69. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. 2005. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care 9:R53.
70. Firmida MC, Pereira RH, Silva EA, Marques EA, Lopes AJ. 2016. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis. Brazilian Journal of Medical and Biological Research 49.
71. Glass MB, Gee JE, Steigerwalt AG, Cauvoti D, Barton T, Hardy RD, Godoy D, Spratt BG, Clark TA, Wilkins PP. 2006. Pneumonia and septicemia caused by Burkholderia thailandensis in the United States. Journal of clinical microbiology 44:4601-4.
72. Han JK, Kerschner JE. 2001. Streptococcus milleri: an organism for head and neck infections and abscess. Archives of Otolaryngology–Head & Neck Surgery 127:650-4.
73. Parkins MD, Sibley CD, Surette MG, Rabin HR. 2008. The Streptococcus milleri group—an unrecognized cause of disease in cystic fibrosis: a case series and literature review. Pediatric pulmonology 43:490-7.
74. Yakut N, Kepenekli EK, Karaaslan A, Atici S, Akkoc G, Demir SO, Soysal A, Bakir M. 2016. Bacteremia due to Acinetobacter ursingii in infants: reports of two cases. Pan African Medical Journal 23.
75. Tetz V, Tetz G. 2018. Draft Genome Sequence of Chryseobacterium mucoviscidosis sp. nov. Strain VT16-26, Isolated from the Bronchoalveolar Lavage Fluid of a Patient with Cystic Fibrosis. Genome announcements. 6:e01473-17.
76. Tetz G, Tetz V. 2017. Draft genome sequence of Bacillus obstructivus VT-16-70 isolated from the bronchoalveolar lavage fluid of a patient with chronic obstructive pulmonary disease. Genome announcements. 5:e01754-16.
77. Galera-Laporta L, García-Ojalvo J. 2020. Antithetic population response to antibiotics in a polymicrobial community. Science Advances. 16:eecaaz5108.
78. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, Becker K, Hays JP, Woodford N, Mitsakakis K, Moran-Gilad J. 2019. Developmental roadmap for antimicrobial susceptibility testing systems. Nature Reviews Microbiology. 17:51-62.
79. Battleman DS, Callahan M, Thaler HT. 2002. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Archives of Internal Medicine. 162:682-8.

80. Walsh TJ, Belitsos NJ, Hamilton SR. 1986. Bacterial esophagitis in immunocompromised patients. Archives of internal medicine 146:1345-8.

81. Torre D, Crespi E, Bernasconi M, Rapazzini P. 2005. Urinary tract infection caused by Kluyvera ascorbata in an immunocompromised patient: case report and review. Scandinavian journal of infectious diseases 37:375-8.

82. Bassetti M, Montero JG, Paiva JA. 2018. When antibiotic treatment fails 1-3.

83. Samanta S, Poddar B, Azim A, Singh RK, Gurjar M, Baronia AK. 2018. Significance of Mini Bronchoalveolar Lavage Fluid Amylase Level in Ventilator-Associated Pneumonia: A Prospective Observational Study. Critical care medicine 46:71-8.

84. Tetz G, Tetz V. 2017. Introducing the sporobiota and sporobiome. Gut pathogens 9:38.

85. Stewart EJ. 2012. Growing unculturable bacteria. Journal of bacteriology 194:4151-60.

86. Le Dorze M, Gault N, Foucrier A, Ruppé E, Mourvillier B, Woerther PL, Birgand G, Montravers P, Dilly MP, Tubach F, Andremont A. 2015. Performance and impact of a rapid method combining mass spectrometry and direct antimicrobial susceptibility testing on treatment adequacy of patients with ventilator-associated pneumonia. Clinical Microbiology and Infection 21:468-e1.